- Home
- TURN vs SRZN Comparison
TURN vs SRZN Comparison
Compare TURN & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- SRZN
- Stock Information
- Founded
- TURN 1981
- SRZN 2015
- Country
- TURN United States
- SRZN United States
- Employees
- TURN N/A
- SRZN N/A
- Industry
- TURN Finance/Investors Services
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- TURN Finance
- SRZN Health Care
- Exchange
- TURN Nasdaq
- SRZN Nasdaq
- Market Cap
- TURN 39.6M
- SRZN 33.0M
- IPO Year
- TURN N/A
- SRZN N/A
- Fundamental
- Price
- TURN $4.05
- SRZN $11.20
- Analyst Decision
- TURN
- SRZN Strong Buy
- Analyst Count
- TURN 0
- SRZN 2
- Target Price
- TURN N/A
- SRZN $38.50
- AVG Volume (30 Days)
- TURN 41.0K
- SRZN 28.0K
- Earning Date
- TURN 03-04-2025
- SRZN 04-09-2025
- Dividend Yield
- TURN N/A
- SRZN N/A
- EPS Growth
- TURN N/A
- SRZN N/A
- EPS
- TURN N/A
- SRZN N/A
- Revenue
- TURN $194,813.00
- SRZN $10,000,000.00
- Revenue This Year
- TURN N/A
- SRZN N/A
- Revenue Next Year
- TURN N/A
- SRZN N/A
- P/E Ratio
- TURN N/A
- SRZN N/A
- Revenue Growth
- TURN 254.25
- SRZN N/A
- 52 Week Low
- TURN $3.12
- SRZN $6.00
- 52 Week High
- TURN $4.47
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- TURN 56.61
- SRZN 49.20
- Support Level
- TURN $3.85
- SRZN $11.25
- Resistance Level
- TURN $4.20
- SRZN $12.55
- Average True Range (ATR)
- TURN 0.14
- SRZN 0.97
- MACD
- TURN -0.00
- SRZN 0.11
- Stochastic Oscillator
- TURN 64.29
- SRZN 55.74
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).